Seeking Alpha

Sangamo BioSciences gives genome modification patent update

  • The U.S. Patent Office issues a notice of allowance for a claim covering "core architectural aspects of engineered Transcription Activator-Like Effectors."
  • Sangamo BioSciences (SGMO) says it expects the architectures "to be broadly adopted and become the industry standard."
  • The technology can be used to edit gene sequences when used with the company's "proprietary engineered FokI nucleases, or DNA cutting domains." (PR)
Comments (1)
  • tomogren
    , contributor
    Comments (3) | Send Message
    Wow! Can you even imagine how big this will be?
    14 Aug 2013, 02:40 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs